Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
JHOP - March 2023 Vol 13 Special Feature
DOWNLOAD EDITORIAL PDF
Download Hopa Abstracts PDF
Editorial
HOPA Abstracts
Editorial
Keeping the HOP(A) Live—Annual Conference Research Highlights
By Mark L. Zangardi, PharmD, MS, BCOP; Sara Kim, PharmD, BCOP
Read More
HOPA Abstracts
Clinical Pharmacist–Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
Read More
Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Who Received Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices
Read More
Evaluation of the Safety of the New Alcohol-Containing Formulation of Cyclophosphamide
Read More
Health System Specialty Pharmacy Integration Impact on Prescription Fill Time
Read More
Invasive Fungal Disease in Patients with Hematologic Malignancies Receiving Micafungin Prophylaxis
Read More
Knowledge Gaps and Educational Needs for Common Cancer Therapy–Related Cardiovascular Adverse Events and Related Drug Interactions
Read More
Multidisciplinary Approach in Maximizing Oncology Clinic Throughput in a Comprehensive Cancer Center
Read More
Optimization of Rasburicase Dose for the Management of Tumor Lysis Syndrome in Community Oncology Practices
Read More
Pharmacist-Led 14-Day Oncolytic Drug Check-In Protocol
Read More
Safety of Rapid Dose Escalation of Venetoclax in Patients with Hematologic Malignancies
Read More
Safety Outcomes of Oxaliplatin Rapid-Rate Infusion versus Standard-Rate Infusion
Read More
Strategies for Implementing an Oral Medication Adherence Intervention
Read More
Effectiveness of High-Dose Intravenous Acyclovir in Preventing Cytomegalovirus Infection in Allogeneic Stem-Cell Transplantation Recipients: A Retrospective Study in a Medical Center in Singapore
Read More
Trilaciclib Use and Chemotherapy-Induced Myelosuppression Among Patients with Extensive-Stage Small-Cell Lung Cancer in US Community Oncology Settings
Read More
Urinary Tract Infections in Patients Receiving Chemotherapy and SGLT2 Inhibitors
Read More
Use of Ursodiol for SOS/VOD Prophylaxis in Patients with Acute Leukemia Receiving Gemtuzumab-Ozogamicin or Inotuzumab-Ozogamicin
Read More
Use of Bevacizumab Originator versus Biosimilar Drugs for Oncology Indications in a Real-World Data Sample
Read More
Veterans Health Administration Pharmacy Benefits Management Anti-Cancer Stewardship Pilot: Why Switch to a Second-Line Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia?
Read More
Assessment and Education of Biosimilars Across an Outpatient Oncology Infusion Network
Read More
Optimizing Corticosteroid Use for Immune-Related Adverse Events at a Community Oncology Practice
Read More
Efficacy of Tixagevimab-Cilgavimab in Preventing SARS-CoV-2 in Patients with Hematologic Malignancies
Read More
Potentially Inappropriate Medication Use and Cognition in Older Women with Breast Cancer
Read More
Safety and Tolerability of an Alternative Capecitabine Dosing Schedule in Patients with Colorectal Cancer
Read More
Biosimilar Uptake and Cost-Savings Analysis Before and After the Implementation of a Pharmacist-Driven Substitution Program Within a National Community Oncology Network
Read More
Bruton Tyrosine Kinase Inhibitors: Real-World Clinical Outcomes in a Diverse Patient Population at a Large Safety Net Hospital
Read More
Clinical Outcomes in Patients with Tumor PD-L1 Less Than 1% Who Received First-Line Nivolumab plus Ipilimumab and 2 Cycles of Chemotherapy versus Chemotherapy Alone for Metastatic NSCLC: Results from CheckMate 9LA
Read More